Skip To Main Content
Kevin C. Oeffingera on Muck Rack

Kevin C. Oeffingera

As seen in: The Oncologist
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kevin C.

Contact Kevin C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cardiac Safety of Dual Anti‐HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2‐Positive Breast Cancer

|
By Jennifer E. Liua, Richard M. Steingarta, Anne Eatonb, Kevin C. Oeffingera
| The Oncologist Verified
Disclosures of potential conflicts of interest may be found at the end of this article. Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)?positive breast cancer, but cardiac safety data is limited. We report the cardiac safety of dose?dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel, trastuzumab, and pertuzumab (THP) in the neoadjuvant setting followed by adjuvant trastuzumab?based therapy.
Open in Who Shared Issue with article?
See all 1 articles